US President Donald Trump issued a multi-part executive order on Tuesday to lower drug prices and reduce Medicare costs.
Within 60 days, the Secretary of Health and Human Services is instructed to seek guidance for the Medicare Drug Price Negotiation Program for initial price applicability year 2028 and how drugmakers should implement the set prices in 2026, 2027, and 2028.
This guidance will focus on greater transparency, selecting high-cost drugs, and safeguarding pharmaceutical innovation.
Additionally, the administration seeks to eliminate a key disparity in how Medicare treats small-molecule drugs compared to biologics, discouraging investment in more affordable treatments.
Also Read: Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines …Full story available on Benzinga.com
